Boundless Bio Reports Q3 2025 Financial Results with Reduced Net Loss

Boundless Bio, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $13.9 million, a decrease from the $16.5 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $45.3 million, down from $48.9 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $15.1 million for the quarter, compared to $18.7 million in Q3 2024. The company’s research and development expenses fell to $10.7 million from $14.1 million year-over-year, reflecting a strategic shift in focus and reduced spending on certain clinical trials.

In terms of financial position, Boundless Bio's total assets decreased to $168.7 million as of September 30, 2025, down from $206.4 million at the end of 2024. The decline in cash and cash equivalents was notable, dropping to $15.0 million from $26.6 million. The company’s accumulated deficit increased to $246.8 million, highlighting the ongoing challenges in achieving profitability. The decrease in cash reserves is primarily due to operational expenditures, with net cash used in operating activities amounting to $36.6 million for the nine months ended September 30, 2025, compared to $45.3 million in the same period of 2024.

Strategically, Boundless Bio has made significant changes to its clinical development programs. The company has prioritized its efforts on the BBI-355 and BBI-825 combination therapy in the ongoing POTENTIATE trial, while winding down other arms of the trial that were not yielding favorable results. Additionally, the company has streamlined operations, including a workforce reduction, to extend its cash runway through critical proof-of-concept milestones. As of September 30, 2025, Boundless Bio had cash, cash equivalents, and short-term investments totaling $117.6 million, which the company believes will be sufficient to fund operations into the first half of 2028.

Looking ahead, Boundless Bio is focused on advancing its ecDNA-directed therapeutic candidates (ecDTx) and developing its ecDNA diagnostic, ECHO. The company plans to submit an investigational new drug application for its Kinesin program, BBI-940, in the first half of 2026. However, the company acknowledges the inherent risks and uncertainties in drug development, including the potential for delays in clinical trials and regulatory approvals. Boundless Bio continues to seek additional funding through equity offerings and collaborations to support its ongoing operations and development efforts.